Clinical Trials

Key Inclusion Criteria:

- Histologically or cytologically confirmed metastatic or unresectable solid tumor.
- Measurable disease by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST
v1.1) as assessed by the Investigator.
- Have progressed on or after all prior standard-of-care therapies for metastatic
disease.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1.
- Adequate organ and marrow function as defined in the protocol.

Key Exclusion Criteria:

- Participant is known to have a mutation that has no expectation of benefit from
VVD-130037. Current such mutations include the following:

1. KEAP1 nonsense mutation (any position)
2. KEAP1 frameshift mutation (any position)

- Any unresolved toxicity Grade ≥2 per CTCAE version 5.0 from previous anticancer
treatment.
- Current or prior treatment with anti-epileptic medications for the treatment or
prophylaxis of seizures.
- History of seizure or condition that may predispose to seizure.
- History or presence of central nervous system (CNS) metastases or spinal cord
compression.
- Uncontrolled arterial hypertension despite optimal medical management.
- Risk factors for abnormal heart rhythm/QT prolongation as defined in the protocol.
- History of the following cardiac diseases:

i) congestive heart failure (New York Heart Association [NYHA] Class >II), ii)
unstable angina, iii) new onset angina within past 6 months, iv) myocardial Infarction
within the past 6 months, v) clinically significant arrhythmias within past 6 months.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 12/1/23. Questions regarding updates should be directed to the study team contact.